The -174 G/C Gene Polymorphism in Interleukin-6 is Associated with an Aggressive Breast Cancer Phenotype

Overview

Journal Br J Cancer

Specialty Oncology

Date 2004 Jan 22

PMID 14735187

Citations 18

Authors

B Iacopetta

F Grieu

D Joseph

Affiliations

Soon will be listed here.

Abstract

Serum and tissue levels of interleukin-6 (IL-6) have been implicated in the biological phenotype of breast carcinoma. A common G/C polymorphism at position -174 of the IL-6 promoter can influence the expression level of this gene. We therefore investigated for associations between this polymorphism and various phenotypic features in a series of 256 breast cancers. Individuals who were homozygous for the C allele (n=55) were more likely to have higher-grade tumours (P=0.039) with ductal histology (P=0.030) compared to those harbouring at least one wild-type G allele (n=201). Homozygosity for the C allele was also associated with significantly worse overall survival (P=0.031). We conclude that the -174 C allele of IL-6 is associated with a more aggressive breast cancer phenotype.

Citing Articles

The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer.

Martinez-Perez C, Kay C, Meehan J, Gray M, Dixon J, Turnbull A J Pers Med. 2021; 11(11).

PMID: 34834425 PMC: 8624266. DOI: 10.3390/jpm11111073.

STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland.

Slawinska M, Zablotna M, Glen J, Lakomy J, Nowicki R, Sobjanek M Arch Dermatol Res. 2019; 311(9):697-704.

PMID: 31342143 PMC: 6787107. DOI: 10.1007/s00403-019-01952-7.

Genetic Modifiers of the Breast Tumor Microenvironment.

Flister M, Bergom C Trends Cancer. 2018; 4(6):429-444.

PMID: 29860987 PMC: 5990047. DOI: 10.1016/j.trecan.2018.04.003.

Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis.

Peng X, Shi J, Sun W, Ruan X, Guo Y, Zhao L Oncotarget. 2018; 9(15):12351-12364.

PMID: 29552316 PMC: 5844752. DOI: 10.18632/oncotarget.24033.

Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer.

Zhai K, Yang Y, Gao Z, Ding J Oncotarget. 2017; 8(27):44490-44497.

PMID: 28548958 PMC: 5546496. DOI: 10.18632/oncotarget.17771.

References

Fernandez-Real J, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M . Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes. 2000; 49(3):517-20. DOI: 10.2337/diabetes.49.3.517. View

Basolo F, Fiore L, Pollina L, Fontanini G, Conaldi P, Toniolo A . Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies. Clin Cancer Res. 1998; 4(2):381-7. View

Ishihara K, Hirano T . IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002; 13(4-5):357-68. DOI: 10.1016/s1359-6101(02)00027-8. View

Powell B, Piersma D, Kevenaar M, van Staveren I, Themmen A, Iacopetta B . Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset. J Clin Endocrinol Metab. 2003; 88(4):1653-7. DOI: 10.1210/jc.2002-021585. View

Martinez-Escribano J, Moya-Quiles M, Muro M, Montes-Ares O, Frias J, Alvarez-Lopez M . Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res. 2002; 12(5):465-9. DOI: 10.1097/00008390-200209000-00008. View

Basolo F, Fiore L, Fontanini G, Conaldi P, Calvo S, Falcone V . Expression of and response to interleukin 6 (IL6) in human mammary tumors. Cancer Res. 1996; 56(13):3118-22. View

Basolo F, Conaldi P, Fiore L, Calvo S, Toniolo A . Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma. Int J Cancer. 1993; 55(6):926-30. DOI: 10.1002/ijc.2910550609. View

Hefler L, Grimm C, Ackermann S, Malur S, Radjabi-Rahat A, Leodolter S . An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003; 63(12):3066-8. View

Vickers M, Green F, Terry C, Mayosi B, Julier C, Lathrop M . Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res. 2002; 53(4):1029-34. DOI: 10.1016/s0008-6363(01)00534-x. View

10.

Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano E, Scalerta R . -174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res. 2003; 9(6):2173-6. View

11.

Fontanini G, Campani D, Roncella M, Cecchetti D, Calvo S, Toniolo A . Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. Br J Cancer. 1999; 80(3-4):579-84. PMC: 2362311. DOI: 10.1038/sj.bjc.6690394. View

12.

Grieu F, Joseph D, Norman P, Iacopetta B . Development of a rapid genotyping method for single nucleotide polymorphisms and its application in cancer studies. Oncol Rep. 2004; 11(2):501-4. View

13.

Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin J, Humphries S . The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998; 102(7):1369-76. PMC: 508984. DOI: 10.1172/JCI2629. View

14.

Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J . Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003; 63(13):3560-6. View

15.

Zheng C, Huang D, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M . Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol. 2000; 109(1):39-45. DOI: 10.1046/j.1365-2141.2000.01963.x. View

16.

Soong R, Iacopetta B, Harvey J, Sterrett G, Dawkins H, Hahnel R . Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer. 1998; 74(6):642-7. DOI: 10.1002/(sici)1097-0215(19971219)74:6<642::aid-ijc15>3.0.co;2-7. View

17.

Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A . Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer. 2000; 88(9):2061-71. View

18.

Terry C, Loukaci V, Green F . Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000; 275(24):18138-44. DOI: 10.1074/jbc.M000379200. View

19.

Zhang G, Adachi I . Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999; 19(2B):1427-32. View

20.

Chapman C, Beilby J, Humphries S, Palmer L, Thompson P, Hung J . Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population. Eur Heart J. 2003; 24(16):1494-9. DOI: 10.1016/s0195-668x(03)00313-0. View